Stock Track | Include the stock name, movement type (pre-market soar), movement percentage, and key reason (strong revenue growth from weight-loss offerings)

Stock Track

Feb 26, 2025

1: Describe the stock movement

2: Explain the movement reasons based on the Q4 results and Q1 outlook

3: Mention the potential impact from the FDA announcement last week

Hims & Hers Soars 5.09% in Pre-Market on Strong Revenue Growth from Weight-Loss Offerings

Hims & Hers Health Inc. (HIMS) stock soared 5.09% in Wednesday's pre-market session, recovering from last week's selloff after reporting robust fourth-quarter results and an upbeat outlook, driven by robust demand for its weight-loss products.

The telehealth company's revenue skyrocketed to $481.1 million in the fourth quarter, up from $246.6 million a year earlier, fueled by strong sales of its GLP-1 weight-loss treatments. For the full year 2024, Hims & Hers' revenue surged 69% to $1.48 billion. Looking ahead to the first quarter of 2025, the company forecasted revenue between $520 million and $540 million and adjusted operating earnings of $55 million to $65 million.

However, Hims & Hers' stock had tumbled 22% last week after the Food and Drug Administration determined that the shortage of popular weight-loss drugs Wegovy and Ozempic had been resolved, potentially impacting the demand for the company's offerings. Nonetheless, investors seem encouraged by the company's robust performance and upbeat guidance, driving the pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118064358"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118064358\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118064358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118064358","market":"hk","top_or_hot":-1,"title":"Stock Track | Include the stock name, movement type (pre-market soar), movement percentage, and key reason (strong revenue growth from weight-loss offerings)","media":"Stock Track","content":"<p>1: Describe the stock movement</p>\n<p>2: Explain the movement reasons based on the Q4 results and Q1 outlook</p>\n<p>3: Mention the potential impact from the FDA announcement last week</p>\n</answer>\n\n<answer>\n<news_title>Hims & Hers Soars 5.09% in Pre-Market on Strong Revenue Growth from Weight-Loss Offerings</news_title>\n\n<news_content>\n<p>Hims & Hers Health Inc. (HIMS) stock soared 5.09% in Wednesday's pre-market session, recovering from last week's selloff after reporting robust fourth-quarter results and an upbeat outlook, driven by robust demand for its weight-loss products.</p>\n\n<p>The telehealth company's revenue skyrocketed to $481.1 million in the fourth quarter, up from $246.6 million a year earlier, fueled by strong sales of its GLP-1 weight-loss treatments. For the full year 2024, Hims & Hers' revenue surged 69% to $1.48 billion. Looking ahead to the first quarter of 2025, the company forecasted revenue between $520 million and $540 million and adjusted operating earnings of $55 million to $65 million.</p>\n\n<p>However, Hims & Hers' stock had tumbled 22% last week after the Food and Drug Administration determined that the shortage of popular weight-loss drugs Wegovy and Ozempic had been resolved, potentially impacting the demand for the company's offerings. Nonetheless, investors seem encouraged by the company's robust performance and upbeat guidance, driving the pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Include the stock name, movement type (pre-market soar), movement percentage, and key reason (strong revenue growth from weight-loss offerings)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Include the stock name, movement type (pre-market soar), movement percentage, and key reason (strong revenue growth from weight-loss offerings)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>1: Describe the stock movement</p>\n<p>2: Explain the movement reasons based on the Q4 results and Q1 outlook</p>\n<p>3: Mention the potential impact from the FDA announcement last week</p>\n</answer>\n\n<answer>\n<news_title>Hims & Hers Soars 5.09% in Pre-Market on Strong Revenue Growth from Weight-Loss Offerings</news_title>\n\n<news_content>\n<p>Hims & Hers Health Inc. (HIMS) stock soared 5.09% in Wednesday's pre-market session, recovering from last week's selloff after reporting robust fourth-quarter results and an upbeat outlook, driven by robust demand for its weight-loss products.</p>\n\n<p>The telehealth company's revenue skyrocketed to $481.1 million in the fourth quarter, up from $246.6 million a year earlier, fueled by strong sales of its GLP-1 weight-loss treatments. For the full year 2024, Hims & Hers' revenue surged 69% to $1.48 billion. Looking ahead to the first quarter of 2025, the company forecasted revenue between $520 million and $540 million and adjusted operating earnings of $55 million to $65 million.</p>\n\n<p>However, Hims & Hers' stock had tumbled 22% last week after the Food and Drug Administration determined that the shortage of popular weight-loss drugs Wegovy and Ozempic had been resolved, potentially impacting the demand for the company's offerings. Nonetheless, investors seem encouraged by the company's robust performance and upbeat guidance, driving the pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1118064358","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118064358","pubTimestamp":1740567654,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Soars 5.09% in Pre-Market on Strong Revenue Growth from Weight-Loss Offerings. Hims & Hers Health Inc.  stock soared 5.09% in Wednesday's pre-market session, recovering from last week's selloff after reporting robust fourth-quarter results and an upbeat outlook, driven by robust demand for its weight-loss products.The telehealth company's revenue skyrocketed to $481.1 million in the fourth quarter, up from $246.6 million a year earlier, fueled by strong sales of its GLP-1 weight-loss","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票轨迹包括股票名称、变动类型（盘前飙升）、变动百分比和关键原因（减肥产品收入强劲增长）","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"1: Describe the stock movement\n2: Explain the movement reasons based on the Q4 results and Q1 outlook\n3: Mention the potential impact from the FDA announcement last week\n\nHims & Hers Soars 5.09% in Pre-Market on Strong Revenue Growth from Weight-Loss Offerings\n\nHims & Hers Health Inc. (HIMS) stock soared 5.09% in Wednesday's pre-market session, recovering from last week's selloff after reporting robust fourth-quarter results and an upbeat outlook, driven by robust demand for its weight-loss products.\nThe telehealth company's revenue skyrocketed to $481.1 million in the fourth quarter, up from $246.6 million a year earlier, fueled by strong sales of its GLP-1 weight-loss treatments. For the full year 2024, Hims & Hers' revenue surged 69% to $1.48 billion. Looking ahead to the first quarter of 2025, the company forecasted revenue between $520 million and $540 million and adjusted operating earnings of $55 million to $65 million.\nHowever, Hims & Hers' stock had tumbled 22% last week after the Food and Drug Administration determined that the shortage of popular weight-loss drugs Wegovy and Ozempic had been resolved, potentially impacting the demand for the company's offerings. Nonetheless, investors seem encouraged by the company's robust performance and upbeat guidance, driving the pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}